Article information
Full text is only aviable in PDF
References
[1.]
M. Humbert, O. Sitbon, G. Simonneau.
Treatment of pulmonary arterial hypertension.
N Engl J Med, 351 (2004), pp. 1425-1436
[2.]
R.J. Barst, L.J. Rubin, W.A. Long, M.D. McGoon, S. Rich, D.B. Badesch, et al.
A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group.
N Engl J Med, 334 (1996), pp. 296-302
[3.]
D.B. Badesch, V.F. Tapson, M.D. McGoon, B.H. Brundage, L.J. Rubin, F.M. Wigley, et al.
Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial.
Ann Intern Med, 132 (2000), pp. 425-434
[4.]
H. Olschewski, G. Simonneau, N. Galie, T. Higenbottan, R. Naeije, L. Rubin, et al.
Inhaled iloprost for severe pulmonary hypertension.
N Engl J Med, 347 (2002), pp. 322-329
[5.]
G. Simonneau, R.J. Barst, N. Galie, R. Naeije, S. Rich, R. Bourge, et al.
Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial.
Am J Respir Crit Care Med, 165 (2002), pp. 800-804
[6.]
M. Gomberg-Maitland, V.F. Tapson, R.L. Benza, V.V. McLaughlin, A. Krichman, A.C. Widlitz, et al.
Transition from intravenous epoprostenol to intravenous treprostinil in pulmonary hypertension.
Am J Respir Crit Care Med, 172 (2005), pp. 1586-1589
[7.]
R.J. Barst, M. McGoon, V. McLaughlin, V. Tapson, R. Oudiz, S. Shapiro, et al.
Beraprost therapy for pulmonary arterial hypertension.
J Am Coll Cardiol, 41 (2003), pp. 2119-2125
[8.]
R.N. Channick, G. Simonneau, O. Sitbon, I.M. Robbins, A. Frost, V.F. Tapson, et al.
Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study.
Lancet, 358 (2001), pp. 1119-1123
[9.]
L.J. Rubin, D.B. Badesch, R.J. Barst, N. Galie, C.M. Black, A. Keogh, et al.
Bosentan therapy for pulmonary arterial hypertension.
N Engl J Med, 346 (2002), pp. 896-903
[10.]
N. Galie, D. Badesch, R. Oudiz, G. Simonneau, M.D. McGoon, A.M. Keogh, et al.
Ambrisentan therapy for pulmonary arterial hypertension.
J Am Coll Cardiol, 46 (2005), pp. 529-535
[11.]
R.J. Barst, D. Langleben, D. Badesch, A. Frost, E.C. Lawrence, S. Shapiro, et al.
Treatment of pulmonary arterial hypertension with the selective endothelin-A receptor antagonist sitaxsentan.
J Am Coll Cardiol, 47 (2006), pp. 2049-2056
[12.]
J. Wharton, J.W. Strange, G.M. Moller, E.J. Growcott, X. Ren, A.P. Franklyn, et al.
Antiproliferative effects of phosphodiesterase type 5 inhibition in human pulmonary artery cells.
Am J Respir Crit Care Med, 172 (2005), pp. 105-113
[13.]
N. Galie, H.A. Ghofrani, A. Torbicki, R.J. Barst, L.J. Rubin, D. Badesch, et al.
Sildenafil citrate therapy for pulmonary arterial hypertension.
N Engl J Med, 353 (2005), pp. 2148-2157
[14.]
O. Sitbon, V.V. McLaughlin, D.B. Badesch, R.J. Barst, C. Black, N. Galie, et al.
Survival in patients with class III idiopathic pulmonary arterial hypertension treated with first line oral bosentan compared with an historical cohort of patients started on intravenous epoprostenol.
Thorax, 60 (2005), pp. 1025-1030
[15.]
V.V. McLaughlin, O. Sitbon, D.B. Badesch, R.J. Barst, C. Black, N. Galie, et al.
Survival with first-line bosentan in patients with primary pulmonary hypertension.
Eur Respir J, 25 (2005), pp. 244-249
[16.]
S. Provencher, O. Sitbon, M. Humbert, S. Cabrol, X. Jais, G. Simonneau.
Long-term outcome with first-line bosentan therapy in idiopathic pulmonary arterial hypertension.
Eur Heart J, 27 (2006), pp. 589-595
[17.]
A. Roman, P. Gispert, V. Monforte, C. Bravo, E. Domingo, F. Morell.
Resultados a largo plazo del tratamiento con bosentán en la hipertensión arterial.
Arch Bronconeumol, 42 (2006), pp. 616-620
[18.]
D.B. Badesch, N.S. Hill, G. Burgess, L.J. Rubin, R.J. Barst, N. Galiè, et al.
Sildenafil for pulmonary arterial hypertension associated with connective tissue disease.
J Rheumatol, 34 (2007), pp. 2417-2422
[19.]
F. Reichenberger, R. Voswinckel, B. Enke, M. Rutsch, E.E. Fechtali, T. Schmehl, et al.
Long-term treatment with sildenafil in chronic thromboembolic pulmonary hypertension.
Eur Respir J, 30 (2007), pp. 922-927
[20.]
G. Otero, A.M. Blanco, A.A. Souto, S. Raposo, H.H. Verea.
Hipertensión pulmonar: eficacia clínica del sildenafilo en clases funcionales II-III.
Arch Bronconeumol, 43 (2007), pp. 272-276
[21.]
K.F. Croom, M.P. Curran, S.H. Abman, R.N. Channick, G.A. Heresi, L.J. Rubin, et al.
Sildenafil: a review of its use in pulmonary arterial hypertension.
Drugs, 68 (2008), pp. 383-397
[22.]
M. Ueno, T. Miyauchi, S. Sakai, R. Yamauchi-Kohno, K. Goto, I. Yamaguchi.
A combination of oral endothelin-A receptor antagonist and oral prostacyclin analogue is superior to each drug alone in ameliorating pulmonary hypertension in rats.
J Am Coll Cardiol, 40 (2002), pp. 175-181
[23.]
M. Humbert, R.J. Barst, I.M. Robbins, R.N. Channick, N. Galiè, A. Boonstra, et al.
Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2.
Eur Respir J, 24 (2004), pp. 353-359
[24.]
V.V. McLaughlin, R.J. Oudiz, A. Frost, V.F. Tapson, S. Murali, R.N. Channick, et al.
Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension.
Am J Respir Crit Care Med, 174 (2006), pp. 1257-1263
[25.]
M.M. Hoeper, H. Leuchte, M. Halank, H. Wilkens, F.J. Meyer, H.J. Seyfarth, et al.
Combining inhaled iloprost with bosentan in patients with idiopathic pulmonary arterial hypertension.
Eur Respir J, 28 (2006), pp. 691-694
[26.]
M.M. Hoeper, N. Taha, A. Bekjarova, R. Gatzke, E. Spiekerkoetter.
Bosentan treatment in patients with primary pulmonary hypertension receiving nonparenteral prostanoids.
Eur Respir J, 22 (2003), pp. 330-334
[27.]
H.J. Seyfarth, H. Pankau, S. Hammerschmidt, J. Schauer, H. Wirtz, J. Winkler.
Bosentan improves exercise tolerance and Tei index in patients with pulmonary hypertension and prostanoid therapy.
Chest, 128 (2005), pp. 709-713
[28.]
M.M. Hoeper, C. Faulenbach, H. Golpon, J. Winkler, T. Welte, J. Niedermeyer.
Combination therapy with bosentan and sildenafil in idiopathic pulmonary arterial hypertension.
Eur Respir J, 24 (2004), pp. 1007-1010
[29.]
S.C. Mathai, R.E. Girgis, M.R. Fisher, H.C. Champion, T. Housten-Harris, A. Zaiman, et al.
Addition of sildenafil to bosentan monotherapy in pulmonary arterial hypertension.
Eur Respir J, 29 (2007), pp. 469-475
[30.]
G.A. Paul, J.S. Gibbs, A.R. Boobis, A. Abbas, M.R. Wilkins.
Bosentan decreases the plasma concentration of sildenafil when coprescribed in pulmonary hypertension.
Br J Clin Pharmacol, 60 (2005), pp. 107-112
[31.]
G. Burgess, H. Hoogkamer, L. Collings, J. Dingemanse.
Mutual pharmacokinetic interactions between steady-state bosentan and sildenafil.
Eur J Clin Pharmacol, 64 (2008), pp. 43-50
[32.]
M. Humbert, E.S. Segal, D.G. Kiely, J. Carlsen, B. Schwierin, M.M. Hoeper.
Results of European post-marketing surveillance of bosentan in pulmonary hypertension.
Eur Respir J, 30 (2007), pp. 338-344
[33.]
N. Galie, L. Rubin, M. Hoeper, P. Jansa, H. Al-Hiti, G. Meyer, et al.
Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial.
Lancet, 371 (2008), pp. 2093-2100
[34.]
L. Stiebellehner, V. Petkov, K. Vonbank, G. Funk, P. Sxhenk, R. Ziesche, et al.
Long-term treatment with oral sildenafil in addition to continuous IV epoprostenol in patients with pulmonary arterial hypertension.
Chest, 123 (2003), pp. 1293-1295
[35.]
K.P. Kuhn, N.E. Wickersham, I.M. Robbins, D.W. Byrne.
Acute effects of sildenafil in patients with primary pulmonary hypertension receiving epoprostenol.
Exp Lung Res, 30 (2004), pp. 135-145
[36.]
G. Simonneau, L.J. Rubin, N. Galie, R.J. Barst, T. Fleming, G. Burgess, et al.
Safety and efficacy of sildenafil-epoprostenol combination therapy in patients with pulmonary arterial hypertension [abstract].
Am J Respir Crit Care Med, 175 (2007), pp. A300
[37.]
H. Wilkens, A. Guth, J. Konig, N. Forestier, B. Cremers, B. Hennen, et al.
Effect of inhaled iloprost plus oral sildenafil in patients with primary pulmonary hypertension.
Circulation, 104 (2001), pp. 1218-1222
[38.]
H.A. Ghofrani, R. Wiedemann, F. Rose, H. Olschewski, R. Schermuly, N. Weissmann, et al.
Combination therapy with oral sildenafil and inhaled iloprost for severe pulmonary hypertension.
Ann Intern Med, 136 (2002), pp. 515-522
[39.]
H.A. Ghofrani, F. Rose, R.T. Schermuly, H. Olschewski, R. Wiedemann, A. Kreckel, et al.
Oral sildenafil as long-term adjunct therapy to inhaled iloprost in severe pulmonary arterial hypertension.
J Am Coll Cardiol, 42 (2003), pp. 158-164
[40.]
M. Gomberg-Maitland, V. McLaughlin, M. Gulati, S. Rich.
Efficacy and safety of sildenafil added to treprostinil in pulmonary hypertension.
Am J Cardiol, 96 (2005), pp. 1334-1336
[41.]
K. Miwa, T. Matsubara, Y. Uno, T. Yasuda, K. Sakata, T. Tsuda, et al.
Combination therapy with oral sildenafil and beraprost for pulmonary arterial hypertension associated with CREST syndrome.
Int Heart J, 48 (2007), pp. 417-422
[42.]
D.B. Badesch, S.H. Abman, G.S. Ahearn, R.J. Barst, D.C. McCrory, G. Simonneau, et al.
Medical therapy for pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines.
Chest, 126 (2004), pp. 35S-62S
[43.]
D.B. Badesch, S.H. Abman, G. Simonneau, L.J. Rubin, V.V. McLaughlin.
Medical therapy for pulmonary arterial hypertension: updated ACCP evidence-based clinical practice guidelines.
Chest, 131 (2007), pp. 1917-1928
[44.]
N. Galie, A. Torbicki, R. Barst, P. Dartevelle, S. Haworth, T. Higenbottam, et al.
Guidelines on diagnosis and treatment of pulmonary arterial hypertension. The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology.
Eur Heart J, 25 (2004), pp. 2243-2278
[45.]
J.A. Barberà, P. Escribano, P. Morales, M.A. Gómez, M. Oribe, A. Martínez, et al.
Estándares asistenciales en hipertensión pulmonar. Documento de consenso elaborado por la Sociedad Española de Neumología y Cirugía Torácica (SEPAR) y la Sociedad Española de Cardiología (SEC).
Arch Bronconeumol, 44 (2008), pp. 87-99
[46.]
M.M. Hoeper, A.T. Dinh-Xuan.
Combination therapy for pulmonary arterial hypertension: still more questions than answers.
Eur Respir J, 24 (2004), pp. 339-340
[47.]
M.M. Hoeper, I. Markevych, E. Spiekerkoetter, T. Welte, J. Niedermeyer.
Goal-oriented treatment and combination therapy for pulmonary arterial hypertension.
Eur Respir J, 26 (2005), pp. 858-863
Copyright © 2009. Sociedad Española de Neumología y Cirugía Torácica
